Evidence Review
Anti-Inflammatory: Clinical Trials and Meta-Analysis
The 2017 RCT by Javadi et al. (PMID 27710596) enrolled 50 women with stable rheumatoid arthritis and randomized them to 500 mg quercetin or placebo daily for 8 weeks. The quercetin group showed significant reductions in early morning stiffness (p < 0.001), morning pain (p = 0.001), and post-activity pain (p = 0.001), along with decreased serum TNF-α. C-reactive protein trended lower but did not reach significance, possibly due to study size. This was a well-designed double-blind trial with objective biomarkers alongside subjective symptom reports.
The 2020 meta-analysis by Ou et al. (PMID 31213101) pooled data from multiple RCTs and found significant reductions in CRP among participants receiving quercetin, particularly at doses above 500 mg/day and in populations with elevated baseline inflammation. Effect sizes were modest in absolute terms, which is typical for dietary interventions, but the directionality was consistent across trials.
Mast Cell Stabilization: Comparison with Pharmaceutical Cromolyn
Weng et al. (PMID 22470478) conducted both in vitro and human studies comparing quercetin to cromolyn sodium, a pharmaceutical mast cell stabilizer used for allergic conditions. In human mast cell cultures, quercetin inhibited IL-8 and TNF release more effectively than cromolyn at equivalent concentrations. In a small human study, topical quercetin reduced contact dermatitis and photosensitivity reactions. The mechanism involves blockade of calcium influx into mast cells and suppression of NF-κB signaling. This study is notable for using head-to-head comparison with an established pharmaceutical rather than placebo alone.
Senolytic Research: First Human Trial
The landmark Mayo Clinic trial by Hickson et al. (PMID 31542391) was the first clinical study to show that senolytics actually reduce senescent cell burden in living humans. Eleven patients with diabetic kidney disease received three intermittent 3-day courses of dasatinib (100 mg/day) plus quercetin (1,000 mg/day). Adipose tissue biopsies before and after showed significant reductions in p16^INK4a and p21^CIP1 expression (markers of cellular senescence), reduced SA-β-galactosidase activity, and decreased SASP factors. Physical function also improved on several measures. This was an uncontrolled pilot study (n=11, no placebo arm), so results must be interpreted cautiously — but the effect on tissue biomarkers was biologically meaningful. Ongoing larger trials are building on this foundation.
Cardiovascular: Blood Pressure Meta-Analysis
Serban et al. (PMID 27405810), published in the Journal of the American Heart Association, pooled 7 RCTs involving 587 patients. Quercetin supplementation produced a weighted mean reduction of −3.04 mmHg in systolic blood pressure (95% CI: −5.26 to −0.82 mmHg, p = 0.007). The effect was more pronounced in trials using doses above 500 mg/day and in participants with higher baseline blood pressure. Diastolic blood pressure changes were non-significant. A 3 mmHg reduction in population-level SBP corresponds to meaningfully reduced cardiovascular event rates, though individual effects will vary.
Antiviral Evidence
Di Pierro et al. (PMID 34194240) conducted a pilot RCT of 42 COVID-19 outpatients randomized to quercetin phytosome (500 mg twice daily) plus standard care or standard care alone. The quercetin group had significantly shorter time to viral clearance, lower hospitalization rates, and reduced symptom severity. Limitations include small sample size, open-label design, and the specific phytosome formulation used. The antiviral mechanism is thought to involve interference with viral proteases and zinc ionophore activity (quercetin may help shuttle zinc into cells, where it inhibits RNA polymerase). This is preliminary evidence and should not be interpreted as a treatment recommendation.
Bioavailability: Why Form Matters
Graefe et al. (PMID 11361045) conducted a pharmacokinetic study in humans comparing quercetin aglycone (pure quercetin powder) to quercetin-4'-glucoside from onions and quercetin-3-rutinoside from buckwheat. The onion-derived glucoside was absorbed significantly faster (Tmax ~0.9 hours vs. 7+ hours) and to a greater absolute extent than the aglycone. Rutinoside had the poorest absorption. This has practical implications: quercetin supplements using standard quercetin powder may have lower bioavailability than food sources or specialized formulations. "Quercetin phytosome" (bound to phosphatidylcholine) and quercetin combined with bromelain are common approaches to improving absorption in supplements.
Overall Evidence Assessment
Quercetin has a solid evidence base for anti-inflammatory and mast cell–stabilizing effects, with human RCT data supporting modest but real-world-relevant benefits. The senolytic research is early-stage but scientifically compelling — it's among the only compounds with human biopsy evidence of reducing senescent cell burden. Cardiovascular benefits appear real but modest. Bioavailability varies significantly by formulation. Safety profile is excellent at doses up to 1,000 mg/day in short- to medium-term studies.